Ovoca Bio PLC
LSE:OVB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Teledyne Technologies Inc
NYSE:TDY
|
US |
Ovoca Bio PLC
Research & Development
Ovoca Bio PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ovoca Bio PLC
LSE:OVB
|
Research & Development
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Research & Development
-$95.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Research & Development
-$782.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-19%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Research & Development
-$39.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Research & Development
-$38.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-158%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Research & Development
-€32.1m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-3%
|
|
Ovoca Bio PLC
Glance View
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.
See Also
What is Ovoca Bio PLC's Research & Development?
Research & Development
0
EUR
Based on the financial report for Dec 31, 2024, Ovoca Bio PLC's Research & Development amounts to 0 EUR.
